A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of the study drug known as
LY2875358, administered alone or in combination with a second drug named Erlotinib, in
participants affected by a defined type of lung cancer (MET biomarker diagnostic positive
Non-Small-Cell Lung Cancer) that experienced a disease progression during the most recent
treatment with Erlotinib.